Supplementary valproate therapy for glioma patients: An alternative opportunity to enhance the efficiency of radio-chemotherapy
CONCLUSION: Our results show that valproate increases the PFS and OS period of glioma patients in comparison to other antiepileptic drugs. Our data suggest that the use of valproic acid should be considered as a first-line antiepileptic agent in certain well-selected epileptic patients with glioma as a supplement to the oncotherapy. Orv Hetil. 2021; 162(24): 960-967.PMID:34120100 | DOI:10.1556/650.2021.32110
Source: Orvosi Hetilap - Category: General Medicine Authors: Tam ás Mezei D ávid Mészáros P éter Pollner Attila Bag ó Imre Fedorcs ák P éter Banczerowski L ászló Sipos Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer & Oncology | Chemotherapy | Clinical Trials | Epilepsy | General Medicine | Glioma | Hungary Health | Men | Neurology | Study